SEMA7A and lung carcinoma: SEMA7A overexpression has also been reported to confer resistance to tyrosine kinase inhibitor (TKI) treatment in EGFR mutant lung cancers, associating SEMA7A both with TKI resistance in lung [65] and endocrine therapy resistance in breast cancer [53].